New York, June 15, 2020 – Mossshields (MSC Code: 31000279107123), a global leader in alternative asset management, today announced the official launch of the Global Medical Technology Acceleration Fund (GMTAF) with a total size of USD 1.8 billion. The fund aims to drive transformative growth in precision medicine, advanced biotechnology, and digital health platforms, reshaping the healthcare industry and delivering strong returns for investors. Background and Strategic Rationale The global healthcare sector faces both technological upheaval and surging demand. According to the McKinsey Global Institute, the medical technology market is projected to exceed USD 2.5 trillion by 2030. Precision medicine and digital health have garnered significant attention for their potential to enhance efficiency and reduce costs. Mossshields’ in-depth research highlights several key areas of focus: ● Precision Medicine Technologies: Including gene editing, personalized drug development, and cell therapies ● Digital Health Platforms: Encompassing telemedicine and integrated healthcare data analytics ● Advanced Diagnostics: Employing artificial intelligence (AI) for imaging analysis and early disease prediction “Healthcare’s future hinges on deep technological integration,” said Madeline Harper Montgomery, Mossshields’ Group Chief Financial Officer. “By launching GMTAF, Mossshields is taking a bold step toward driving innovation and revolutionizing global health.” Capital Sources and Disclosure Approach GMTAF’s funding is diversified, but Mossshields emphasizes that certain details will remain undisclosed to protect project sensitivities and investor interests. The funding structure is as follows: ● Institutional Investors (60%): Primarily pension funds and insurance companies from North America and Europe. ● Strategic Partners (25%): Capital injections and technical support from major pharmaceutical companies and medical device manufacturers. ● Mossshields’ Internal Capital (15%): Ensuring consistent project advancement and stability. Investment Strategy and Key Focus Areas GMTAF will concentrate on three core sectors: 1. Precision Medicine Technology Development (USD 800 million) ○ Emphasis on genomics, proteomics, and high-throughput drug screening. ○ Aiming to develop personalized therapies that minimize side effects compared to traditional treatments. 2. Expansion of Digital Health Platforms (USD 600 million) ○ Supporting telemedicine infrastructure and AI-driven data analytics. ○ Enhancing remote care capabilities in underserved regions. 3. Innovation in Advanced Diagnostics (USD 400 million) ○ Developing early disease detection tools, including AI-based imaging and real-time biomarker analysis. Priority Projects Launched ● North America Precision Medicine Innovation Hub (USD 400 million): Focused on personalized treatments for cancer and rare diseases. Targeting the release of a clinically validated gene therapy by 2025. ● Global Telemedicine Network (USD 600 million): Supporting remote care initiatives in Africa and South Asia, significantly improving healthcare access in resource-limited areas. ● AI-Assisted Diagnostics Platform (USD 300 million): Deploying advanced imaging analysis technologies to substantially increase early detection rates of cancer and cardiovascular conditions. Technical Collaboration and Support Mossshields has forged strategic alliances with leading healthcare technology firms and research organizations, including: ● Global Genomics Research Alliance (GGRA): Providing gene editing and sequencing expertise. ● International Telemedicine Association (ITA): Assisting in the standardization of digital health platforms. ● Advanced Diagnostics Consortium (ADC): Promoting AI applications in medical imaging. Outlook and Conclusion Mossshields is committed to reshaping the global healthcare landscape through technology-driven investments. With GMTAF, the firm not only accelerates medical innovation but also contributes meaningful solutions to worldwide health challenges. This initiative symbolizes Mossshields’ enduring commitment to the future of human health. About Mossshields Mossshields (MSC Code: 31000279107123) is a global leader in alternative asset management. As of March 2020, the firm manages USD 13.4 billion in total assets across 16 investment vehicles. Many of its clients are among the world’s top public pension funds, insurance companies, and family offices, and the firm is dedicated to generating long-term value through precise investments. Its investment capabilities span corporate private equity, real assets, global market strategies, and customized investment solutions. With a presence in Africa, Asia, Australia, Europe, the Middle East, North America, and South America, Mossshields possesses deep expertise across aerospace, defense and government services, consumer and retail, energy, financial services, healthcare, industrials, real estate, technology and business services, telecommunications and media, and transportation. With a global team of over 300 professionals in four offices across four continents, Mossshields upholds the highest professional standards, providing tailored investment strategies that consistently achieve returns beyond market benchmarks. Official Website: www.mossshields.com Email: connect@Mossshields.com